Retatrutide

Retatrutide (LY3437943) is a novel triple-agonist peptide developed by Eli Lilly that simultaneously targets glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. This multi-receptor approach distinguishes it from single-agonist compounds like semaglutide (GLP-1 only) and dual-agonists like tirzepatide (GIP/GLP-1). **Mechanism of Action** The compound's triple-receptor mechanism produces complementary effects: GLP-1 receptor activation slows gastric emptying and enhances satiety signaling; GIP receptor activation appears to improve insulin sensitivity and lipid metabolism; glucagon receptor activation increases hepatic glucose production acutely while enhancing energy expenditure through thermogenesis and promoting hepatic lipid oxidation (Finan et al., 2015). **Clinical Research** Phase 2 clinical... Read more